165 results about "Proteinoid" patented technology

The invention relates to the technical field of plant genetic engineering, and particularly provides cloning of a GbGELP25D gene of gossypium barbadense and application of the GbGELP25D gene of gossypium barbadense. According to the invention, the GbGELP25D gene with a full length of 1092 bp is cloned from the sea island cotton variety Xinhai No. 7 for the first time, and the gene encodes a secretory lipase protein with a signal peptide and is positioned in an extracellular gap. Through bioinformatics analysis, phylogenetic classification, protein structure modeling and signal peptide function verification, it is clear that the gene belongs to a plant GELP family. Furthermore, a virus-induced gene silencing technology is utilized to prove that the silent GbGELP25D can obviously enhance the resistance of cotton to verticillium wilt, and the mechanism of the silent GbGELP25D is closely related to activation of ethylene synthesis and signal channels and induction of expression of disease-resistant related genes. The resistance gene provided by the invention enriches gene resources of cotton verticillium wilt resistance breeding, and has important theoretical significance and application value.

A composition that can activate both a class B and class C G-protein-coupled receptor (GPCR) simultaneously is described herein. This composition can be used in a variety of methods, and is exemplified by a HYBD-HEXA peptide, which is found in SEQ ID NO: 1.

A method for generating binding peptides presented by any given Major Histocompatibility Complex (MHC) protein is presented. The method includes, given a peptide and an MHC protein pair, enabling a Reinforcement Learning (RL) agent to interact with and exploit a peptide mutation environment by repeatedly mutating the peptide and observing an observation score of the peptide, learning to form a mutation policy, via a mutation policy network, to iteratively mutate amino acids of the peptide to obtain desired presentation scores, and generating, based on the desired presentation scores, qualified peptides and binding motifs of MHC Class I proteins.

The present disclosure provides thiazolidine (Tz) linkers for protein-drug conjugates. In addition, the disclosure also encompasses compounds useful for producing such protein-drug conjugates, as well as methods for production of such protein-drug conjugates. The disclosure also encompasses methods of using the protein-drug conjugates for the treatment of a disease or disorder in a subject.

The present disclosure relates to formulations comprising a protein comprising an Fc region (e.g., an antibody) and a surfactant such as a polysorbate (e.g., Polysorbate 20), and methods of purifying such proteins that improve stability of the surfactant such as a polysorbate in such formulations.

Provided herein are proteins, which are capable of being transported across the blood- brain barrier (BBB) and comprise an acid alpha-glucosidase (GAA) enzyme-Fc fusion polypeptide. Certain embodiments also provide methods of using such proteins to treat Pompe disease.

A hybrid protein comprises a first domain comprising a sequence encoding a surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain. The hybrid protein or an mRNA encoding such protein can be used as a vaccine against the infection of the enveloped RNA virus.

The present application relates to ANXA3 protein targeted degradation chimera and its preparation method and application. Specifically, the present application relates to ANXA3 protein targeted degradation chimera, or its pharmaceutically acceptable salt, or its stereoisomer, or a pharmaceutical composition composed of a medically acceptable carrier, and the use in preparing ANXA3 protein targeted degradation chimera and the use in preparing drugs for preventing and / or treating breast cancer. The present application utilizes the PROTAC technology to provide a kind of ANXA3 protein targeted degradation chimera, which can combine ANXA3 protein, selectively degrade ANXA3 protein, inhibit the proliferation of breast cancer cells in vitro, and play the role of anti-breast cancer. Breast cancer refers to breast cancer molecular subtypes such as triple negative, Luminal A type, Luminal B type, Her2+ type.

Immunoglobulin complementarity determining regions ("CDRs"), and immunoglobulin binding domains comprising those CDRs, that bind human lymphocyte antigen 6 family member G6D (LY6G6D), and their use for the preparation of LY6G6D-binding proteins finding use as immunotherapeutics.

The present invention provides novel markers of the severity of a central nervous system injury, such as spinal cord injury or traumatic brain injury, in a patient. In particular, protein components of inflammasomes in the cerebrospinal fluid that can be used to assess the severity of central nervous system injury in a patient are disclosed. Methods of using such protein biomarkers to determine a prognosis, direct treatment and rehabilitation efforts, and monitor response to treatment for a patient with a central nervous system injury are also described.

This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and / or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and / or such a signal; to select ISV's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and / or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal; —methods for modifying and / or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; —modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er) / reduced tendency to give rise to such protein interference or such a signal; modified and / or improved ISV's that have no or a low(er) / reduced tendency to give rise to such protein interference or such a signal.

The invention relates to the technical field of spreading modes of human viruses, in particular to a virus spreading mode prediction model based on interaction of virus protein and human protein, a prediction model construction method and a prediction method. The method specifically comprises the following steps: S1, constructing a training data set of a virus transmission mode; s2, based on the data in the S1, obtaining a virus-human protein interaction prediction result, vectorizing the prediction result by using 0 / 1 coding, and constructing a virus-human protein interaction matrix; and S3, using a machine learning algorithm and a feature selection project to construct and train a virus propagation mode prediction model based on the interaction of the virus protein and the human protein. The method for predicting the virus propagation mode of interaction between the virus protein and the human protein is convenient to use and wide in application range; the method is especially suitable for new viruses or unknown viruses which are not fully researched, and can realize efficient and rapid propagation mode identification.

The invention discloses judgment and optimization of key amino acid sites for controlling sesquiterpene synthesis, and determines amino acid residues lysine or arginine or glutamine related to sesquiterpene synthesis for point mutation and combined mutation of various plant sesquiterpene synthase. Lysine or arginine or glutamine is located in a cavity among 5-10 amino acids in front of the first long alpha helix at the N end, alpha helixes (also the longest alpha helix in the protein) communicating the N end and the C end of the protein and the last 1-7 amino acids at the C end at the site. The method for determining the key amino acid can be used for efficiently screening the sesquiterpene synthase with activity, and the optimization of the amino acid of the key residue can be used for guiding the transformation of the high-yield sesquiterpene synthase for industrial production. The invention has important application value and economic benefit in the fields of biological synthase identification of sesquiterpenoids, biosynthesis of drugs, fermentation production of spices, synthesis of industrial raw materials and the like.

The invention belongs to the technical field of protein and polypeptide, and particularly relates to a protein / polypeptide sustained-release agent, sustained-release protein and polypeptide as well as a preparation method and application thereof. According to the specific technical scheme, the protein / polypeptide sustained-release agent is any one of benzoic acid debranched starch crystals, phosphorylated debranched starch crystals or OSA debranched starch crystals. On the basis of DBS, an anionic phosphate group, an amphiphilic OSA group and a cationic benzoic acid group are respectively introduced into hydroxyl sites of DBS through a debranched starch modification reaction, then low-humidity temperature-control induced crystallization is performed, and a protein / polypeptide loading strategy based on starch molecular chain restrictive recombination is provided for the first time and is suitable for various proteins / polypeptides. The chemically modified DBS can successfully load the protein / polypeptide, so that the protein / polypeptide is effectively protected, and the slow release of the protein / polypeptide is realized. Compared with unmodified DBS, the modified DBS has higher protein / polypeptide loading rate and longer release time.

This invention discloses a genetically engineered bacterium for synthesizing carotenoids, its construction method, and its applications, belonging to the field of genetic engineering technology. The genetically engineered bacterium uses a carotenoid-producing yeast strain as the starting material. The gene ROX1, encoding a heme-dependent hypoxia gene repressor, is knocked out, while the expression of genes STB5 (encoding a transcription factor involved in NADPH regeneration), DID2 (encoding a class E protein in the vacuole protein sorting pathway), and VOA1 (encoding an endoplasmic reticulum protein playing a role in the assembly of the V0 region of V-ATPase) is upregulated. This invention promotes carotenoid synthesis and significantly increases carotenoid yield through combined regulation of gene expression outside the carotenoid synthesis pathway, demonstrating promising application prospects.

The disclosure provides biomarker panels, methods and kits for determining the probability for preterm birth in a pregnant female. The present disclosure is based, in part, on the discovery that certain proteins and peptides in biological samples obtained from a pregnant female are differentially expressed in pregnant females that have an increased risk of developing in the future or presently suffering from preterm birth relative to matched controls. The present disclosure is further based, in part, on the unexpected discovery that panels combining one or more of these proteins and peptides can be utilized in methods of determining the probability for preterm birth in a pregnant female with relatively high sensitivity and specificity. These proteins and peptides disclosed herein serve as biomarkers for classifying test samples, predicting a probability of preterm birth, monitoring of progress of preterm birth in a pregnant female, either individually or in a panel of biomarkers.

Provided are novel recombinant proteins that are capable of self-crystallization and exhibit desirable physical properties such as enhanced cellular uptake or and endoso-mal escape. Polynucleotides encoding the recombinant proteins as well as methods of making and using such proteins are also described.

It was discovered herein that neither the nuclear localization signal (NLS) nor the prion-like domain (PLD) of TDP-43 are required for in vitro embryonic stem cell culture and differentiation into motor neurons. ES cells expressing these TDP-43 mutants and differentiated into motor neurons that exhibit an ALS-like phenotype, from which the TDP-43 mutants redistribute to and accumulate in the cytoplasm, and the inability to regulate cryptic exon splicing, such that these cells can serve as a model for TDP-43 proteinopathies for testing candidate therapeutics that can dissipate such proteinopathies. In addition, these ES cells can be used to successfully generate non-human animals, e.g., mice, that also exhibit hallmark symptoms of ALS and can be used to test candidate agents useful for treating TDP-43 proteinopathies.

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

The invention relates to proteases exhibiting proteolytic activity and comprising an amino acid sequence that, over its total length, corresponds to the amino acid sequence specified in SEQ ID NO:1 by at least 70% and increasingly preferably by at least 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 90.5%, 91%, 91.5%, 92%, 92.5%, 93%, 93.5%, 94%, 94.5%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5% and 98% is identical, wherein the protease, with reference to the numbering according to SEQ ID NO:1, has at least one amino acid substitution at at least one of the positions corresponding to positions 97, 3, 99, 127 and 211, which is selected from the group consisting of N97E, R99E, R99I, R99N, R99V, R99T, D127E and M211C. Such proteases are suitable for use in washing and cleaning agents, in particular liquid textile detergents, and exhibit improved cleaning performance compared to a reference protease.The invention further relates to the use of these proteases and processes in which they are used, as well as washing and cleaning agents containing them, in particular liquid textile detergents.

Immunoglobulin complementarity determining regions ("CDRs"), and immunoglobulin binding domains comprising those CDRs, that bind human lymphocyte antigen 6 family member G6D (LY6G6D), for the preparation of multispecific LY6G6D / CD3 binding proteins and their use in a multispecific format with a CD3-binding moiety.

The present invention generally relates to improved protease-activatable antigen-binding molecules that comprise an anti-idiotype-binding moiety which reversibly masks a CD3 antigen binding moiety of the molecule. In addition, the present invention relates to polynucleotides encoding such protease-activatable T cell binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell binding molecules of the invention, and to methods of using the same, e.g., in the treatment of disease.

Described herein are methods of treatment with myosin inhibitors based on protein levels; methods of monitoring response to treatment based on such protein levels; and methods of determining whether to treat a patient with a myosin inhibitor based on such protein levels. Such methods may include obtaining a biological sample of a subject, measuring one or more protein levels in the sample, analyzing the one or more protein levels, and determining the therapeutic response based on the analysis, and may also include treating the subject based on the determination of a therapeutic response.

The application discloses a kind of amide bond synthesis enzyme mutant and its application in catalyzing synthesis of drug intermediate, the mutant is P328A-T421L, and its amino acid sequence is as shown in SEQ ID NO:5.A kind of amide bond synthesis enzyme mutant in catalyzing synthesis of drug intermediate, with 2-methylthiazole-5-carboxylic acid and L-O-methyl serine as substrate, with mutant P328A-T421L or the mutant P328A shown in SEQ ID NO:3 as catalyst, drug intermediate is obtained in one step reaction, and the drug intermediate is O-methyl-N-(2-methylthiazole-5-formyl)-L-serine (MTCS).The performance of the mutant of the application compared with wild type, the performance of catalyzing synthesis of peptide epoxy ketone proteasome inhibitor oplazomib core chiral precursor MTCS is greatly improved, and conversion rate is increased from 26.8% of wild type to 76.1%.

The application provides an AR protein degradation agent and a preparation method and application thereof. Specifically, the application provides a compound as shown in formula I or a pharmaceutically acceptable salt, stereoisomer, geometric isomer, hydrate, solvate, prodrug thereof. The compound of the application has superior target protein degradation efficiency and stronger anti-tumor cell proliferation effect.

The present invention relates to novel DLL3 / CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.

Provided are proteins and molecules comprising a variant Fc region or a variant CH2 domain with significantly reduced binding to FcγR family receptors and reduced effector functions. Methods of producing and using such proteins and molecules are also provided.

The invention provides an MITF protein degradation agent and application thereof, and particularly provides a compound or a pharmaceutically acceptable salt thereof, or a stereoisomer or a prodrug thereof, and the compound is shown as a formula (I). The compound can degrade MITF protein in a targeted manner through a ubiquitin-proteasome way, so that the compound can be used for treating indications mediated by abnormal expression of the MITF protein.